- Mitsubishi Chemical plans to launch ZELAS™ AMP in 2027.
- The research involves Kyushu University and Osaka University.
- ZELAS™ AMP aims to reduce anticoagulant use and coating costs.
- The key polymer combines blood compatibility and substrate affinity.
Research Collaboration
Mitsubishi Chemical Corporation (MCC) has initiated a joint research project with Kyushu University and Osaka University. The focus is on applying the antithrombogenic thermoplastic elastomer, ZELAS™ AMP, to medical devices.
Objective and Benefits
The aim is to launch ZELAS™ AMP in 2027, targeting global expansion. This elastomer seeks to reduce the use of anticoagulants and eliminate the need for costly coating processes in medical devices, such as cardiac catheters and cardiopulmonary bypass circuits.
Technical Details
ZELAS™ AMP features an amphiphilic polymer that combines blood compatibility and substrate affinity. By integrating this polymer into base materials like polyvinyl chloride and polyurethane, the elastomer imparts antithrombogenic properties, low protein adsorption, and low bacterial adhesion.
Research Focus
The collaboration will explore optimal addition and formulation design of ZELAS™ AMP for various resins used in medical devices. The goal is to enhance the safety and functionality of blood-contacting medical devices.
